Evidence map›Paper›PMID 36506588›Full record

ArticleFrontiers in pharmacology2022

Hepatoprotective effect of botanical drug formula on high-fat diet-induced non-alcoholic fatty liver disease by inhibiting lipogenesis and promoting anti-oxidation.

De-Shan Ning, Yu-Ju Chen, Chien-Ju Lin, Ching-Chiung Wang, Hong-Wei Zhao, Kun-Teng Wang, Ming-Chung Lee, Lemmuel L Tayo, Wan-Chun Chiu, Chiu-Li Yeh and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Metabolomics Reveals the Anti-hepatic Fibrosis Mechanisms ofInternational journal of medical sciences · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

De-Shan NingInfinitus (China) Company Ltd., Guangzhou, China.
Yu-Ju ChenPh.D. Program in Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taipei, Taiwan.
Chien-Ju LinSchool of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
Ching-Chiung WangPh.D. Program in Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taipei, Taiwan.
Hong-Wei ZhaoInfinitus (China) Company Ltd., Guangzhou, China.
Kun-Teng WangHerbiotek Co., Ltd., New Taipei City, Taiwan.
Ming-Chung LeeHerbiotek Co., Ltd., New Taipei City, Taiwan.
Lemmuel L TayoSchool of Chemical, Biological Materials Science and Engineering, Mapúa University, Manila, Philippines.
Wan-Chun ChiuSchool of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan.
Chiu-Li YehSchool of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan.
Chia-Jung LeePh.D. Program in Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taipei, Taiwan.
Taipei Medical University · TWInfinitus (China) · CNKaohsiung Medical University · TWMapúa University · PHTaipei Medical University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the prevalence of obesity and other components of metabolic syndrome, Non-alcoholic fatty liver disease (NAFLD) has become increasingly common. In recent years, much attention has been paid to various plant sources, hoping to find a treatment for NAFLD in plants. The Livsooth authentic herbal formula (LAH, ), a botanical drug formula combined with Puerariae lobatae radix, Lonicerae japonicae flos, Hoveniae semen, and Siraitiae fructus. This study used a network pharmacology approach to predict the potential mechanisms of LAH against NAFLD. Gene Ontology (GO) and KEGG pathway enrichment analyses have identified potential biochemical and signaling pathways. Subsequently, the potential mechanism of action of LAH on NAFLD predicted by network pharmacology analysis was validated in a high-fat diet (HFD)-induced NAFLD model in C57BL/6 mice. Our results demonstrated that LAH ameliorated hepatocyte steatosis in liver tissue by activating the AMPK pathway and decreasing serum triglycerides, low-density lipoprotein, glucose, and cholesterol. Besides, LAH increased the hepatic antioxidant enzymes activities, suggested that LAH improved oxidative stress markers in HFD induced NAFLD mice.

Indexed as

AMPK pathwayanti-oxidationherb-based supplementsnetwork pharmacologynon-alcoholic fatty liver disease (NAFLD)puerarin

Identifiers

PMID36506588
PMCPMC9729544
OpenAlexW4309916603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.